Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4395-4398

  Stickeler, Elmar ^a,b   Möbus, Volker J ^b   Kieback, Dirk G ^a   Kohlberger, Petra ^c   Runnebaum, Ingo B ^a   Kreienberg, Rolf ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abnormal RNA processing; Alternative splicing; CD44. intron 9 retention; Ovarian cancer

Indexed keywords

CD44V ANTIGEN; HERMES ANTIGEN; MARKER; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 2642605352     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lesley J, Hyman R, Kincade, PW: CD44 and its interaction with extracellular matrix. Adv in Immunology 54: 271-335, 1993.
2. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and osteopontin (ETA-1). Science 271: 509-512, 1996.
3. Taher TEI, Smit L, Griffoen AW, Schilder-Tol EJM, Borst J, Pals S: Signaling through CD44 is mediated by tyrosine kinases. J Biol Chem 271(5): 2863-2867, 1996.
4. Haynes BF, Hua-Xin. L, Patton KL: The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 3: 347-350, 1990.
5. Cannistra S, Abu-Jawdeh G, Niloff J et al: CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors . J Clin Oncol 13: 1912-1921, 1995.
6. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615-619, 1995.
7. Stickeler E, Runnebaum IB, Mobus VJ, Kieback DG, Kreienberg R: Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cells. Anticancer Res 17: 1871-1876, 1997.
8. Sugiyama M, Woodma A, Sugino T et al: Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. J Clin Pathol 48: 142-147, 1995.
9. Wielenga VJM, Heider KH, Offerhaus JA et al: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756, 1993.
10. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164, 1992.
11. Gunthert U. CD44: A multitude of isoforms with diverse functions. Curr Microbiol and Immunol 184: 47-63, 1993.
12. Higashikawa K, Yokozaki H, Ue T et al: Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 66: 11-17, 1996.
13. Matsumura Y, Sugiyama M, Matsumura S et al: Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 177: 11-20, 1996.
14. Yoshida K, Bolodeoku J, Sugino T et al: Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res 55: 4273-4277, 1995.
15. Talerico M, Berget SM: Effect of 5′ splice site mutations on splicing of the preceding intron. Mol Cell Biol 10(12): 6299-6305, 1990.
16. Berget SM: Exon recognition in vertebrate splicing. J Biol Chem 270(6): 2411-14, 1995.
17. Mobus VJ, Asphal WE, Knapstein PG, Kreienberg R: Effects of interferon on the proliferation and modulation of cell surface strucutures of human ovarian cancer cell lines. J Cancer Res Clin Oncol 120: 27-34, 1993.
18. Mobus VJ, Gerharz CD, Press U et al: Morphological and immunhistochemical and biochemical characterization of six newly established human ovarian cancer cell lines. Int J Cancer 52: 76-84, 1994.
19. East JA, Hart IR: CD44 and its role in tumor progression and metastasis. Lancet 1921-1922, 1993.
20. Fox S, Fawcett J, Jackson DG et al: Normal tissue, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54: 4539-4546, 1994.
21. Gunthert U, Hofmann M, Rudy A et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
22. Underhill C: CD44: The hyaluronan receptor. J Cell Science 103: 293-298, 1992.
23. Green MR: Biochemical mechanisms of constitutive and regulated pre-mRNA splicing. Annu Rev Cell Biol 7: 559-599, 1991.
24. Hodges D, Bernstein S: Genetic and biochemical analysis of alternative RNA splicing. Adv Genet 31: 207-254, 1994.